Ernst Holler

TL;DR: The understanding of the risk factors and causes of GHVD, the cellular and cytokine networks implicated in its pathophysiology, and current strategies to prevent and treat the disease are reviewed.

TL;DR: Three patients with hematologic relapse after bone marrow transplantation for chronic myelogenous leukemia were treated with interferon alpha and transfusion of viable donor buffy coat and had complete hematological and cytogenetic remission, which persisted 32 to 91 weeks after treatment, an example of adoptive immunotherapy without cytoreductive chemotherapy or radiotherapy in human chimeras.

TL;DR: The addition of ATG-F to GVHD prophylaxis with ciclosporin and methotrexate resulted in decreased incidence of acute and chronic GV HD without an increase in relapse or non-relapse mortality, and without compromising overall survival.

TL;DR: This study suggests two pathways of TNF alpha release: activation of host macrophages and stimulation of donor cells in the course of acute graft-versus-host disease.

TL;DR: The results confirm that the clinical benefit of donor lymphocyte infusion in the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation (HSCT) is limited to a minority of patients.